One clinical trial (NCT02159716) [41] evaluated the feasibility and safety of anti-MSLN CAR-T cells with and without cyclophosphamide pretreatment in 15 patients, and the results showed that the maximum tolerable dose of anti-MSLN CAR-T cells was 3 × 108 cells/m2 and that there were no targeted toxic reactions, such as pleurisy, pericarditis, and peritonitis. Here, MSLN is linked to pericarditis.